Education
About Us
Working with TipRanks
Follow Us
Race Oncology Ltd. (AU:RAC)
ASX:RAC
RAC Stock Chart & Stats
AU$2.82
-AU$0.03(-2.27%)
At close: 4:00 PM EST
AU$2.82
-AU$0.03(-2.27%)
Day’s Range― - ―
52-Week RangeAU$0.92 - AU$4.90
Previous CloseN/A
Volume68.10K
Average Volume (3M)373.28K
Market Cap
AU$509.91M
Enterprise ValueAU$190.48M
Total Cash (Recent Filing)AU$13.67M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding180,818,900
10 Day Avg. Volume310,625
30 Day Avg. Volume373,283
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)12.69
Price to Sales (P/S)33.63
P/FCF Ratio-44.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Race Oncology Ltd. News
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$0.92 and its highest was AU$4.90 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$509.91M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Mar 03, 2026 which is in 67 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Aug 26, 2025. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 180,818,900 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.695%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Race Oncology Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 95%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$115.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.34%
12-Months-Change
Fundamentals
Return on Equity
-27.89%
Trailing 12-Months
Asset Growth
-13.54%
Trailing 12-Months
Company Description
Race Oncology Ltd.
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Technical Analysis
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―